Ligand Acquires Verrow Pharmaceuticals

Ligand Pharmaceuticals Incorporated

Represented Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) with its acquisition of Verrow Pharmaceuticals, Inc. for development of cyclodextrin-enabled imaging contrast agents.

Ligand is a biopharmaceutical company that focuses on developing and/or acquiring technologies that help pharmaceutical companies in discovering and creating medicines. Verrow is a Kansas-based medical invention company that discovers and patents uses of modified cyclodextrins to reduce acute kidney injury during medical interventions

San Diego-based Hayden Trubitt represented Ligand Pharmaceuticals in this transaction.